Company / Named in our posts
Xencor, Inc..
Follow Xencor, Inc.A clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases.[1]
01Deal
Deals on Carrywatch
Every deal that names Xencor, Inc., and its role in each.
OCM Life Sciences Portfolio LP / Xencor, Inc.
OCM Life Sciences Portfolio LP to Purchase Xencor Royalty Rights
See deal detailsDeal Web
Xencor, Inc. and 0 firms it shares a posted deal with, and the path to any other firm.
Financials
5 fiscal years of figures as Xencor, Inc. reported them.
News
Loading headlines.
Sources
As of 24 Oct 2026.
- 01Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
- 02Form 8-K, filed November 7, 2023
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
Deal posts naming Xencor, Inc.:
- P01